Updated:26 May 2017 03:31:00 PM(IST)
|Bse Corporate Announcements||Back|
|Cipla updates on Stempeutics Research, a JV with Cipla Group|
|Cipla announced that Stempeutics Research, a group company of Manipal
Education and Medical Group and a Joint Venture with Cipla Group has been granted a US process patent for its novel stem-cell based drug Stempeucel® by the United States Patent and Trademarks Office (USPTO).
Stempeucel® will initially be used for the treatment of Critical Limb Ischemia (CLI) and is a breakthrough treatment option which directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself.